Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Candidates for inclusion in a universal antiretroviral regimen: dolutegravir

Candidates for inclusion in a universal antiretroviral regimen: dolutegravir Purpose of reviewThe review addresses the role of dolutegravir (DTG) in first-line therapy. In the era of test and treat, where United Nations AIDS Program and WHO have set the ambitious targets of 90/90/90, new efficacious, well tolerated, and simple therapeutic options are needed.Recent findingsDTG has been tested in large clinical trials in treatment-naïve patients, showing noninferiority to raltegravir and superiority compared with efavirenz and ritonavir-boosted darunavir, respectively. The main features of DTG are reviewed in this study, including efficacy, safety, high-resistance barrier, daily treatment schedule, and coformulation as single-tablet regimen. Use of DTG in special populations is also reviewed. Tolerability, with focus in neuropsychiatric disturbances is discussed in particular. DTG has shown high efficacy level, tested in males and females, has no limitations in patients with renal and/or hepatic impairment and is available as single drug (to be combined with two nucleoside reverse transcriptase inhibitors in fixed combinations) or as a single-tablet regimen combined with abacavir and lamivudine.SummaryDTG is an excellent candidate for initial therapy in HIV-infected patients. If safety of DTG in pregnant women are confirmed by ongoing studies, DTG might become the first option in WHO antiretroviral guidelines. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Candidates for inclusion in a universal antiretroviral regimen: dolutegravir

Current Opinion in HIV and Aids , Volume 12 (4) – Jul 1, 2017

Loading next page...
 
/lp/wolters-kluwer-health/candidates-for-inclusion-in-a-universal-antiretroviral-regimen-pQp073RLqz

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000388
pmid
28520610
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewThe review addresses the role of dolutegravir (DTG) in first-line therapy. In the era of test and treat, where United Nations AIDS Program and WHO have set the ambitious targets of 90/90/90, new efficacious, well tolerated, and simple therapeutic options are needed.Recent findingsDTG has been tested in large clinical trials in treatment-naïve patients, showing noninferiority to raltegravir and superiority compared with efavirenz and ritonavir-boosted darunavir, respectively. The main features of DTG are reviewed in this study, including efficacy, safety, high-resistance barrier, daily treatment schedule, and coformulation as single-tablet regimen. Use of DTG in special populations is also reviewed. Tolerability, with focus in neuropsychiatric disturbances is discussed in particular. DTG has shown high efficacy level, tested in males and females, has no limitations in patients with renal and/or hepatic impairment and is available as single drug (to be combined with two nucleoside reverse transcriptase inhibitors in fixed combinations) or as a single-tablet regimen combined with abacavir and lamivudine.SummaryDTG is an excellent candidate for initial therapy in HIV-infected patients. If safety of DTG in pregnant women are confirmed by ongoing studies, DTG might become the first option in WHO antiretroviral guidelines.

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Jul 1, 2017

References